FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
21 | Melanoma in situ: long-term outcomes and follow-up strategies based on risk stratification Beatrice De Checchi1, Paolo del Fiore2, Irene Russo2, Chiara Trevisiol2, Marco Domenico Mazza2, Saveria Tropea2, Francesco Russano2, Mauro Alaibac3, Carlomaria Gianesini4, Giovanni Madeo4, Simone Mocellin2|4 | 1Department of Medicine, University of Padua, Padua; 2Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua; 3Department of Dermatology, University of Padua; 4Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
354 -
Tight junctions in Hailey-Hailey and Darier’s diseases
1632PDF: 662HTML: 1708 -
32 | Tebentafusp in metastatic uveal melanoma: 3 years of real world data and insights from liquid biopsy Luisa Piccin1, Maria Chiara Scaini2, Valentina Salizzato1, Cristina Catoni2, Elisabetta Di Liso1, Alice Menichetti1, Chiara Cacco1|4, Chiara Gottardi1|4, Francesca Di Sarra3, Marina Coppola3, Valentina Guarneri1|4, Jacopo Pigozzo1 | 1Medical Oncology 2 - Veneto Institute of Oncology IOV-IRCCS; 2Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS; 3Pharmacy Unit - Veneto Institute of Oncology IOV-IRCCS; 4Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy.
292 -
12 | Integrated molecular and immunophenotypic profiling of uveal melanoma: prognostic insights and biological perspectives Francesco Fortarezza1, Giovanni Zarrilli2, Giada Munari1, Valentina Angerilli3, Mariangela Balistreri1, Luisa Piccin4, Valentina Salizzato4, Jacopo Pigozzo4, Giulia Midena5, Raffaele Parrozzani6, Valentina Guarneri4|7, Edoardo Midena5|6, Marta Sbaraglia1|8, Matteo Fassan8|9, Angelo Paolo Dei Tos1|8 | 1Surgical Pathology and Cytopathology Unit, Department of Integrated Diagnostics. Azienda Ospedale-Università Padova, Padua; 2Surgical Pathology Unit, Azienda Ulss 3 Serenissima, Ospedale dell'Angelo, Venezia; 3Department of Surgical Pathology, Azienda ULSS2 Marca Trevigiana, Treviso; 4Medical Oncology 2, Veneto Institute of Oncology, IOV-IRCCS, Padua; 5IRCCS-Fondazione Bietti, Rome; 6Department of Ophthalmology, University of Padova, Padova; 7Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua; 8Department of Medicine, University of Padua School of Medicine, Padua; 9Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
341
